Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth

Cancer Cell

Volumn 19, Issue 6, 2011, Pages 765-775

  Miluzio, Annarita ^a   Beugnet, Anne ^a   Grosso, Stefano ^a,b   Brina, Daniela ^a   Mancino, Marilena ^a   Campaner, Stefano ^c   Amati, Bruno ^c,d   de Marco, Ario ^e,f   Biffo, Stefano ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f UNIVERSITY OF NOVA GORICA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTIC INITIATION FACTOR 6; MYC PROTEIN; PROTEIN KINASE C; PROTEIN KINASE C BETA 11; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; EVENT FREE SURVIVAL; GENE AMPLIFICATION; GENE MUTATION; IN VIVO STUDY; LYMPHOMA; LYMPHOMAGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; PROTEIN PHOSPHORYLATION; TRANSLATION INITIATION;

EUKARYOTA; MUS;

EID: 79958709853     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.04.018     Document Type: Article

References (51)

1. Barna M., Pusic A., Zollo O., Costa M., Kondrashov N., Rego E., Rao P.H., Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008, 456:971-975.
2. Biffo S., Sanvito F., Costa S., Preve L., Pignatelli R., Spinardi L., Marchisio P.C. Isolation of a novel beta4 integrin-binding protein (p27(BBP)) highly expressed in epithelial cells. J. Biol. Chem. 1997, 272:30314-30321.
3. Ceci M., Gaviraghi C., Gorrini C., Sala L.A., Offenhäuser N., Marchisio P.C., Biffo S. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature 2003, 426:579-584.
4. Cencic R., Carrier M., Trnkus A., Porco J.A., Minden M., Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk. Res. 2010, 34:535-541.
5. Chaiwatanatorn K., Stamaratis G., Opeskin K., Firkin F., Nandurkar H. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk. Lymphoma 2009, 50:1666-1675.
6. de Marco A., Deuerling E., Mogk A., Tomoyasu T., Bukau B. Chaperone-based procedure to increase yields of soluble recombinant proteins produced in E. coli. BMC Biotechnol. 2007, 7:32.
7. Dephoure N., Zhou C., Villén J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. USA 2008, 105:10762-10767.
8. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., Russo M., Cancelliere C., Zecchin D., Mazzucchelli L., et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 2010, 120:2858-2866.
9. Donadini A., Giacopelli F., Ravazzolo R., Gandin V., Marchisio P.C., Biffo S. GABP complex regulates transcription of eIF6 (p27BBP), an essential trans-acting factor in ribosome biogenesis. FEBS Lett. 2006, 580:1983-1987.
10. Dowling R.J., Topisirovic I., Alain T., Bidinosti M., Fonseca B.D., Petroulakis E., Wang X., Larsson O., Selvaraj A., Liu Y., et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010, 328:1172-1176.
11. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
12. Gandin V., Miluzio A., Barbieri A.M., Beugnet A., Kiyokawa H., Marchisio P.C., Biffo S. Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature 2008, 455:684-688.
13. Gorrini C., Loreni F., Gandin V., Sala L.A., Sonenberg N., Marchisio P.C., Biffo S. Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proc. Natl. Acad. Sci. USA 2005, 102:9200-9205.
14. Gorrini C., Squatrito M., Luise C., Syed N., Perna D., Wark L., Martinato F., Sardella D., Verrecchia A., Bennett S., et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007, 448:1063-1067.
15. Grosso S., Volta V., Sala L.A., Vietri M., Marchisio P.C., Ron D., Biffo S. PKCbetaII modulates translation independently from mTOR and through RACK1. Biochem. J. 2008, 415:77-85.
16. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
17. Iritani B.M., Eisenman R.N. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl. Acad. Sci. USA 1999, 96:13180-13185.
18. Jackson R.J., Hellen C.U., Pestova T.V. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 2010, 11:113-127.
19. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16:205-213.
20. Langdon W.Y., Harris A.W., Cory S., Adams J.M. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 1986, 47:11-18.
21. Leonard J.P., Martin P., Barrientos J., Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin. Hematol. 2008, 45(3, Suppl 2):S11-S16.
22. Mackinnon R.N., Campbell L.J. Dicentric chromosomes and 20q11.2 amplification in MDS/AML with apparent monosomy 20. Cytogenet. Genome Res. 2007, 119:211-220.
23. Miluzio A., Beugnet A., Volta V., Biffo S. Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep. 2009, 10:459-465.
24. Moerke N.J., Aktas H., Chen H., Cantel S., Reibarkh M.Y., Fahmy A., Gross J.D., Degterev A., Yuan J., Chorev M., et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007, 128:257-267.
25. Montanaro L., Treré D., Derenzini M. Nucleolus, ribosomes, and cancer. Am. J. Pathol. 2008, 173:301-310.
26. Narla A., Ebert B.L. Ribosomopathies: human disorders of ribosome dysfunction. Blood 2010, 115:3196-3205.
27. Oliver E.R., Saunders T.L., Tarle S.A., Glaser T. Ribosomal protein L24 defect in belly spot and tail (Bst), a mouse Minute. Development 2004, 131:3907-3920.
28. Park E.H., Zhang F., Warringer J., Sunnerhagen P., Hinnebusch A.G. Depletion of eIF4G from yeast cells narrows the range of translational efficiencies genome-wide. BMC Genomics 2011, 12:68.
29. Perry R.P. The architecture of mammalian ribosomal protein promoters. BMC Evol. Biol. 2005, 5:15.
30. Pestova T.V., Borukhov S.I., Hellen C.U. Eukaryotic ribosomes require initiation factors 1 and 1A to locate initiation codons. Nature 1998, 394:854-859.
31. Pestova T.V., Lomakin I.B., Lee J.H., Choi S.K., Dever T.E., Hellen C.U. The joining of ribosomal subunits in eukaryotes requires eIF5B. Nature 2000, 403:332-335.
32. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 2006, 94:195-199.
33. Ristevski S., O'Leary D.A., Thornell A.P., Owen M.J., Kola I., Hertzog P.J. The ETS transcription factor GABPalpha is essential for early embryogenesis. Mol. Cell. Biol. 2004, 24:5844-5849.
34. Robert F., Pelletier J. Translation initiation: a critical signalling node in cancer. Expert Opin. Ther. Targets 2009, 13:1279-1293.
35. Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res. 2009, 69:8839-8843.
36. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 2004, 10:484-486.
37. Sanvito F., Piatti S., Villa A., Bossi M., Lucchini G., Marchisio P.C., Biffo S. The beta4 integrin interactor p27(BBP/eIF6) is an essential nuclear matrix protein involved in 60S ribosomal subunit assembly. J. Cell Biol. 1999, 144:823-837.
38. Sanvito F., Vivoli F., Gambini S., Santambrogio G., Catena M., Viale E., Veglia F., Donadini A., Biffo S., Marchisio P.C. Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer. Cancer Res. 2000, 60:510-516.
39. Schaffel R., Morais J.C., Biasoli I., Lima J., Scheliga A., Romano S., Milito C., Spector N. PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod. Pathol. 2007, 20:326-330.
40. Sengupta J., Nilsson J., Gursky R., Spahn C.M., Nissen P., Frank J. Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM. Nat. Struct. Mol. Biol. 2004, 11:957-962.
41. Si K., Maitra U. The Saccharomyces cerevisiae homologue of mammalian translation initiation factor 6 does not function as a translation initiation factor. Mol. Cell. Biol. 1999, 19:1416-1426.
42. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266.
43. Soh J.W., Weinstein I.B. Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J. Biol. Chem. 2003, 278:34709-34716.
44. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem. Cell Biol. 2008, 86:178-183.
45. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
46. Stebbins E.G., Mochly-Rosen D. Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C. J. Biol. Chem. 2001, 276:29644-29650.
47. Valenzuela D.M., Chaudhuri A., Maitra U. Eukaryotic ribosomal subunit anti-association activity of calf liver is contained in a single polypeptide chain protein of Mr = 25,500 (eukaryotic initiation factor 6). J. Biol. Chem. 1982, 257:7712-7719.
48. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
49. White R.J. RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 2008, 24:622-629.
50. Yoon A., Peng G., Brandenburger Y., Zollo O., Xu W., Rego E., Ruggero D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
51. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16:369-377.